2024 Rome, Italy

IV-01 Christiane Dings
Mathematical modeling of the oral glucose tolerance test in pre-diabetic patients: An IMI DIRECT study
Thursday 15:25-16:50
IV-02 Anne-Gaelle Dosne
Exposure-response analysis of erdafitinib and pharmacodynamic-guided dose individualization in patients with locally advanced or metastatic urothelial carcinoma
Thursday 15:25-16:50
IV-03 Erwin Dreesen
A population pharmacokinetic and exposure-response model to support therapeutic drug monitoring during vedolizumab induction therapy
Thursday 15:25-16:50
IV-04 Ronan Duchesne
Identifiability in nonlinear mixed effect models: the example of in vitro erythropoiesis
Thursday 15:25-16:50
IV-05 Vincent Duval
A continuous-time Markov model (CTMM) for investigator’s global assessment (IGA) score in moderate-to-severe atopic dermatitis treated with subcutaneous nemolizumab.
Thursday 15:25-16:50
IV-06 Dimitra Eleftheriadou
Aluminium biokinetics: Elucidating the speciation kinetics of the aluminium-citrate system in vitro.
Thursday 15:25-16:50
IV-07 Douglas J. Eleveld
Aging and maturation as a reliability problem: The Weibull distribution and age- and maturation-adjustment functions
Thursday 15:25-16:50
IV-08 Esther Encinas
Use of modeling and simulation methods to support the generic application of a vaginal delivery system
Thursday 15:25-16:50
IV-09 Aline Engbers
Postnatal age, gestational age and small for gestational age drive the pharmacokinetics of ibuprofen enantiomers in very preterm neonates with patent ductus arteriosus
Thursday 15:25-16:50
IV-10 Muhammad Faisal
Simultaneous semi-mechanistic population pharmacokinetic analysis of enalapril and enalaprilat in serum and urine following the administration of child appropriate oro-dispersible mini-tablets.
Thursday 15:25-16:50
IV-11 Undine Falkenhagen
Structural model selection: Is the chi-square distribution appropriate for likelihood ratio tests?
Thursday 15:25-16:50
IV-12 Alan Faraj
Drug effect of clofazimine on persisting mycobacteria explain an unexpected increase in bacterial load from patients
Thursday 15:25-16:50
IV-13 Anam Fayyaz
Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes
Thursday 15:25-16:50
IV-14 Anam Fayyaz
Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes
Thursday 15:25-16:50
IV-15 Rebekka Fendt
Evaluating the benefit of individual patient data for physiologically based pharmacokinetic (PBPK) simulations
Thursday 15:25-16:50
IV-16 Valentina Fermanelli
Correlation structure of Apolipoprotein A4, C3, E kinetics parameters
Thursday 15:25-16:50
IV-17 Chiara Fornari
Importance of stability analysis when using non-linear semi-mechanistic models to describe drug-induced haematotoxicity
Thursday 15:25-16:50
IV-18 Jose Francis
A semi-mechanistic model to characterise the influence of nevirapine- and lopinavir/ritonavir-based therapy on artemether and dihydroartemisinin exposure
Thursday 15:25-16:50
IV-19 Yu Fu
Hemodynamic systems model to characterize cardiovascular drug effects
Thursday 15:25-16:50
IV-20 Aline Fuchs
Assessment of translation of PKPD relationship from animal to human for malaria compounds
Thursday 15:25-16:50
IV-21 Laura Fuhr
Physiologically based pharmacokinetic modeling of the dabigatran antidote idarucizumab
Thursday 15:25-16:50
IV-22 Masato Fukae
Population pharmacokinetic modeling of esaxerenone: a novel nonsteroidal mineralocorticoid receptor blocker
Thursday 15:25-16:50
IV-23 Fanny Gallais
Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies
Thursday 15:25-16:50
IV-24 Fiona G. Gao
Prediction of human pharmacokinetics of subcutaneously administered insulin formulations
Thursday 15:25-16:50
IV-25 Kamunkhwala Gausi
Pharmacokinetics of isoniazid preventative therapy among HIV-infected pregnant women in high tuberculosis incidence settings
Thursday 15:25-16:50
IV-26 Sergey Gavrilov
Longitudinal assessment of tumor size and neutrophil count in multivariate joint models are more predictive of survival than their baseline values in patients with non-small cell lung cancer
Thursday 15:25-16:50
IV-27 Peter Gennemark
Determination of antisense oligonucleotide tissue half-life
Thursday 15:25-16:50
IV-28 Eva Germovsek
A time-to-event model relating integrated craving to risk of smoking relapse across different nicotine replacement therapy formulations
Thursday 15:25-16:50
IV-29 Bill Gillespie
Torsten: Stan functions for pharmacometric applications. New functionality including within chain parallel computation.
Thursday 15:25-16:50
IV-30 Anais Glatard
Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin levels using PK/PD modeling
Thursday 15:25-16:50
IV-31 Ferran Gonzalez
Pharmacokinetic model development for total and free vancomycin in critically ill children
Thursday 15:25-16:50
IV-32 Ignacio Gonzalez-Garcia
Pharmacokinetic/Pharmacodynamic Modelling of in vivo IL-13 Modulation by a monoclonal antibody (MEDI7836)
Thursday 15:25-16:50
IV-33 Mario Gonzalez Sales
Assembling pharmacometric datasets in R: the puzzle package
Thursday 15:25-16:50
IV-34 Katharina Martha Götz
Predictive Systems Medicine Modelling of Myelosuppression and Recovery of Hematopoietic Cells among Adult Patients with Hematopoietic Cell Transplantation
Thursday 15:25-16:50
IV-35 Iztok Grabnar
Oxcarbazepine and its active metabolite 10-monohydroxycarbamazepine clearance maturation in paediatric patients with epilepsy
Thursday 15:25-16:50
IV-36 Silvia Grandoni
Development and evaluation of a PBPK model to study the pharmacokinetics of inhaled drugs in rats
Thursday 15:25-16:50
IV-37 Ana-Marija Grisic
Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study
Thursday 15:25-16:50
IV-38 Jinju Guk
Modelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers
Thursday 15:25-16:50
IV-39 Tingjie Guo
Exploring practical limitations of model-based Bayesian dose optimization in intensive care patients
Thursday 15:25-16:50
IV-40 Stefanie Hamacher
Population pharmacokinetics of cannabidiol in healthy subjects
Thursday 15:25-16:50
IV-41 Felix Hammann
Population pharmacokinetics and generation of dosing nomograms of daptomycin at a Swiss university hospital
Thursday 15:25-16:50
IV-42 Lutz Harnisch
Dose Selection Process for Younger Children Participating in a Phase 3 Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-occlusive Crisis in Hospitalized Patients With Sickle Cell Disease
Thursday 15:25-16:50
IV-43 Paul Healy
PKPD bridging and extrapolation of efficacy for the use of gabapentin and tramadol in paediatric chronic pain.
Thursday 15:25-16:50
IV-44 Guenter Heimann
An Industry Perspective on Extrapolation in Pediatric Drug Development: A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy.
Thursday 15:25-16:50
IV-45 Farina Hellmann
Population pharmacokinetic modelling in Ewing sarcoma patients focussing on etoposide as an example
Thursday 15:25-16:50
IV-46 Emilie Hénin
Therapeutic drug monitoring strategies for Envarsus in de novo renal transplant patients using population modelling and simulations
Thursday 15:25-16:50
IV-47 Charlotte Kloft
Review of NMLE articles published in clinical journals with a higher impact factor
Thursday 15:25-16:50
IV-48 Thomas Henthorn
A population pharmacokinetic model of dense delta-9-tetrahydrocannabinol (THC), 11-OH-THC, and THCCOOH data and its use to estimate daily exposure in an observational cannabis study with sparse data
Thursday 15:25-16:50
IV-49 Lukas Kovar
Physiologically-based pharmacokinetic (PBPK) modelling of nicotine and its main metabolite cotinine in healthy volunteers and smokers
Thursday 15:25-16:50
IV-50 Anneke Himstedt
Prediction of pulmonary exposure based on plasma pharmacokinetics: A comparison of different model-based approaches.
Thursday 15:25-16:50
IV-51 Richard Höglund
Multidrug-resistant genotypes are associated with therapeutic failure of antimalarial therapy in Cambodia; a pharmacometric approach
Thursday 15:25-16:50
IV-52 Nick Holford
Rational dosing of caffeine using target concentration intervention to improve treatment of apnea of prematurity
Thursday 15:25-16:50
IV-53 Chih-hsuan Hsin
Impact of intestinal and renal membrane transporter ABCB1 gene polymorphisms on the pharmacokinetics of digoxin in healthy Caucasian subjects
Thursday 15:25-16:50
IV-54 Ka Ho, Matthew Hui
Evaluation of Parameter Estimation when Fitting a Mixture Model with Covariate Effects using NONMEM
Thursday 15:25-16:50
IV-55 Ziad Hussein
Population Pharmacokinetics of Lemborexant, a Dual Orexin Receptor Antagonist, in Healthy Adult and Elderly Subjects and Subjects with Primary Insomnia
Thursday 15:25-16:50
IV-56 Eman Ibrahim
Obesity and NAFLD activity score increase rate of fibrosis progression in a continuous-time Markov modelling of fibrosis progression in a long-term follow-up biopsy NAFLD cohort.
Thursday 15:25-16:50
IV-57 Hiroyuki Iida
Modelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice
Thursday 15:25-16:50
IV-58 Luis Ilia
Quantitative comparison of in vitro and in vivo variability of microdialysis experiments using nonlinear mixed-effects modelling on the example of linezolid
Thursday 15:25-16:50
IV-59 Khalid Iqbal
Modelling tissue pharmacokinetics: A comparison of empiric and mechanistic PBPK modelling approaches of different complexity exemplified with moxifloxacin
Thursday 15:25-16:50
IV-60 Itziar Irurzun-Arana
ACESO (A Cancer Evolution Simulation Optimizer)
Thursday 15:25-16:50
IV-61 Kris Oliver Jalusic
Pharmacokinetics of vancomycin in the cerebrospinal fluid in critically ill patients
Thursday 15:25-16:50
IV-62 Petra Jauslin
Modeling bounded scales for evaluation of treatment response to subcutaneous nemolizumab in moderate to severe atopic dermatitis
Thursday 15:25-16:50
IV-64 Jin Jin
Model-informed artificial intelligence (AI) solution enabling real-time predictions: towards next generation modeling
Thursday 15:25-16:50
IV-65 Mats Jirstrand
A challenge model of TNFα turnover with LPS provocations and drug intervention
Thursday 15:25-16:50
IV-66 Curtis Johnston
M-EASE-2: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus (T1DM)
Thursday 15:25-16:50
IV-67 Daniel Jonker
The impact of septic shock on the pharmacokinetics and pharmacodynamics of selepressin
Thursday 15:25-16:50
IV-68 Felix Jost
Application of a feedback optimal control algorithm to a population pharmacokinetic-pharmacodynamic model of cytarabine-derived and lenograstim-reduced myelosuppression in acute myeloid leukemia
Thursday 15:25-16:50
IV-69 Fabian Jung
Simulation of the environmental exposure to fenofibrate nanomaterials based on in vitro- and in silico methods
Thursday 15:25-16:50
IV-70 Wannee kantasiripitak
A population pharmacokinetic and exposure-response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis
Thursday 15:25-16:50
IV-71 Evangelos Karakitsios
A methodology to estimate population pharmacokinetic parameters from aggregate concentration-time data and its application to gevokizumab.
Thursday 15:25-16:50
IV-72 Vangelis Karalis
An In Vitro – In Vivo Simulation Methodology for Predicting the Outcome of Bioequivalence Studies
Thursday 15:25-16:50
IV-73 Eleni Karatza
Investigation of the impact of population parameters describing gastric emptying on bioequivalence metrics
Thursday 15:25-16:50
IV-74 Tatiana Karelina
Amyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects
Thursday 15:25-16:50
IV-75 Adrien Tessier
Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part I - simulation study evaluating type I error and power of proof-of-concept trials
Thursday 15:25-16:50
IV-76 Hidefumi Kasai
Tumor Response Index (TRI): model-based prediction of tumor response and survival in metastatic colorectal cancer patients treated by mFOLFOX6 with bevacizumab
Thursday 15:25-16:50
IV-77 Takayuki Katsube
Evaluation of Variance-based Global Sensitivity Analysis for Covariate Effects
Thursday 15:25-16:50
IV-78 Aida Kawuma
Dolutegravir pharmacokinetics in co-administration with rifampicin.
Thursday 15:25-16:50
IV-79 Ron Keizer
Continuous learning in model-informed precision dosing: a case study
Thursday 15:25-16:50
IV-80 Zackary Kenz
Inflammation and Fibrosis in Nonalcoloholic Steatohepatitis (NASH) Characterized by a Mathematical Model
Thursday 15:25-16:50
IV-81 Yun Kim
A population pharmacokinetic/pharmacodynamic analysis of rosuvastatin according to OATP1B1 and BCRP polymorphisms in young and elderly subjects
Thursday 15:25-16:50
IV-82 NaYoung Kim
Development of predictive model for acute kidney injury after minimally invasive partial nephrectomy
Thursday 15:25-16:50
IV-83 Seoyoung Kim
Population Pharmacokinetic-Pharmacodynamic Modeling of Escitalopram in Patients with Obsessive-Compulsive Disorder Using Yale-Brown Obsessive Compulsive Scale
Thursday 15:25-16:50
IV-84 Dohyun Kim
Optimization of dosing strategy for Colistin using population pharmacokinetic model based on the Bayesian inference
Thursday 15:25-16:50
IV-85 Lena Klopp-Schulze
Exposure-response analyses of the bifunctional fusion protein bintrafusp alfa (M7824) in early drug development
Thursday 15:25-16:50
IV-86 Franziska Isabelle Kluwe
Model-based characterisation of nonlinear voriconazole pharmacokinetics following two different routes of administration
Thursday 15:25-16:50
IV-87 Lisa Alina Kneller
Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on Risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach
Thursday 15:25-16:50
IV-88 Stephan Koehne-Voss
A comparison of relative exposure estimates from single trough, multiple trough, and full population PK sampling designs
Thursday 15:25-16:50
IV-89 Galina Kolesova
Application of different approaches to generate virtual patient populations for QSP model of Physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies
Thursday 15:25-16:50